Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macdonald, J. S.
Right arrow Articles by et, al.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdonald, J. S.
Right arrow Articles by et, al.

Annals of Surgical Oncology, Vol 2, Issue 6 488-494, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study

J. S. Macdonald, T. R. Fleming, R. F. Peterson, J. L. Berenberg, S. McClure, R. A. Chapman, H. J. Eyre, D. Solanki, A. B. Cruz Jr, R. Gagliano and al. et
Temple University, Philadelphia, Pennsylvania 19140-5102, USA.

PURPOSE: To evaluate FAM [5-FU (5-fluorouracil), doxorubicin, mitomycin C] chemotherapy as adjuvant therapy for patients with resected TNM stage I, II, or III gastric carcinoma. PATIENTS AND METHODS: One hundred ninety-three eligible patients were accrued from 1978 to 1991 in a phase III trial comparing six cycles (1 year) of postoperative FAM chemotherapy with observation only. RESULTS: The median follow-up on this study was 9.5 years. For all patients, no differences (log-rank analysis) in disease-free survival (p = 0.45) and overall survival (p = 0.57) between FAM therapy (93 cases) and surgery (100 cases) were observed. Quality of surgical resection affected survival irrespective of FAM use. Cases with curative resection, defined in a retrospective review of pathology and surgical reports as cases having no evidence of residual disease in the abdomen and tumor-free margins > 1 cm, had superior survival compared to cases not meeting these requirements (p < 0.001). FAM was well tolerated with 6% (five of 90) of cases demonstrating grade IV hematologic toxicity. There were two drug-related fatalities (one cardiomyopathy, one hematolytic uremic syndrome). CONCLUSION: FAM is not effective adjuvant therapy for TNM stage I, II, and III patients with resected gastric cancer. Future adjuvant studies must emphasize prospective surgical quality control to assure enrollment of appropriately staged and resected cases and wide participation to assure adequate case accrual over a reasonable period.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W.-C. Liao, J.-T. Lin, C.-Y. Wu, S.-P. Huang, M.-T. Lin, A. S.-H. Wu, Y.-J. Huang, and M.-S. Wu
Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma
Clin. Cancer Res., January 15, 2008; 14(2): 428 - 434.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Cunningham, W. H. Allum, S. P. Stenning, J. N. Thompson, C. J.H. Van de Velde, M. Nicolson, J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson, et al.
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N. Engl. J. Med., July 6, 2006; 355(1): 11 - 20.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ohtsu, S. Yoshida, and N. Saijo
Disparities in Gastric Cancer Chemotherapy Between the East and West
J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Hejna, S. Wohrer, M. Schmidinger, and M. Raderer
Postoperative chemotherapy for gastric cancer.
Oncologist, February 1, 2006; 11(2): 136 - 145.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Lim, M. Michael, G. B. Mann, and T. Leong
Adjuvant Therapy in Gastric Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Kollmannsberger, W. Budach, M. Stahl, N. Schleucher, T. Hehr, H. Wilke, J. Schleicher, U. Vanhoefer, E. C. Jehle, K. Oechsle, et al.
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
Ann. Onc., August 1, 2005; 16(8): 1326 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. M. Chang, K. H. Jung, T.-Y. Kim, W. S. Kim, H.-K. Yang, K. U. Lee, K. J. Choe, D. S. Heo, Y.-J. Bang, and N. K. Kim
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer
Ann. Onc., November 1, 2002; 13(11): 1779 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, R. Buzzoni, L. Mariani, E. Beretta, F. Bozzetti, G. Bordogna, E. Aitini, S. Fava, G. Schieppati, G. Pinotti, et al.
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group
Ann. Onc., February 20, 2002; 13(2): 299 - 307.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.